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The Moloney murine leukemia virus (Mo-MLV) enhancer contains binding sites (LVb and LVc) for the ets
gene family of proteins and a core site that binds the polyomavirus enhancer-binding protein 2/core-binding
factor (cbf) family of proteins. The LVb and core sites in the Mo-MLV enhancer contribute to its constitutive
activity in T cells. All three binding sites (LVb, LVc, and core) are required for phorbol ester inducibility of the
Mo-MLV enhancer. Adjacent binding sites for the ets and cbf proteins likewise constitute a phorbol ester
response element within the human T-cell receptor b-chain (TCRb) enhancer and contribute to constitutive
transcriptional activity of the TCRb enhancer in T cells. Here we show that the CBFa subunit encoded by the
mouse Cbfa2 gene (the murine homolog of human AML1) and three ets proteins, Ets-1, Ets-2, and GA-binding
protein (GABP), transactivate both the Mo-MLV and mouse TCRb enhancer in transient-expression assays.
Moreover, we show that transactivation by Cbfa2 requires both intact ets and cbf binding sites. Transactivation
by Ets-1, Ets-2, and GABP likewise requires intact binding sites for ets proteins and CBF. Supportive
biochemical analyses demonstrate that both proteins can bind simultaneously to a composite enhancer
element. These findings suggest that ets and cbf proteins cooperate in vivo to regulate transcription from the
Mo-MLV and TCRb enhancers.
The combinatorial use of transcription factors has emerged
as an important theme in the regulation of eukaryotic gene
expression. A typical promoter and enhancer region has a
diverse array of binding sites for factors. In some cases, the
complexity reflects the many alternative regulatory pathways
that modulate the appropriate tissue-specific and developmen-
tal timing of a particular gene. However, in other cases, it has
become apparent that factors cannot work effectively alone,
but rather have cooperative modes of action. The simplest
form of this synergism is dimers, which occur as both hetero-
and homodimeric combinations. This type of cooperation re-
flects the requirement for a particular DNA-binding motif to
dimerize to acquire DNA-binding competence (e.g., the bZIP
and bHLH proteins). More intriguing are the cases in which
two DNA-binding proteins that belong to two totally different
structural families cooperate to mediate transcriptional activa-
tion. Although many cases of this type of cooperation have
recently been reported (see, for example, references 8, 20, and
31), in no case is the molecular basis for the synergism com-
pletely understood.
The ets family of transcription factors provides several ex-
amples of synergistic partnerships. The ets proteins contain a
structural motif (winged helix-turn-helix) that is capable of
binding DNA as a monomer (15, 46). However, in several
members of the family, the DNA-binding activity appears to be
suboptimal in the absence of a partner protein. For example,
the ets protein Elk-1 activates transcription from the c-fos
promoter in conjunction with the DNA-binding protein serum
response factor (SRF) (30). A specific protein-protein interac-
tion stabilizes the binding of Elk-1 and SRF on the c-fos pro-
moter (32, 33, 65, 68). A different type of partnership is ob-
served in the case of GA-binding protein (GABP), which is
composed of an alpha subunit with an ETS domain and a
non-DNA-binding beta subunit. Two alpha and two beta sub-
units form a stable tetramer with augmented DNA-binding
activity (9, 76). In these two cases, the ets proteins have a
specific partner. A domain has been mapped in Elk-1 and
GABPa that is important in the protein-protein interaction,
and only ets proteins bearing that domain can interact with the
partner. For example, a subset of ets proteins bear the B do-
main (e.g., Elk-1, SAP-1 [30], and NET [21]) and can interact
with SRF. In the case of GABP, only the GABPa subunit, and
no other ets proteins, can interact with GABPb (9).
The partnership requirements of the ets proteins Ets-1 and
the highly related Ets-2 are less well understood. Full-length
Ets-1 contains an inhibitory domain that dampens its DNA-
binding potential (28, 47, 59, 85). Surprisingly, Ets-1 and Ets-2
have been reported to cooperate with several different putative
partners in functional studies. Ets-1 works with Sp1 in activat-
ing transcription from the human T-cell lymphotropic virus
type 1 enhancer (18), while on the immunoglobulin M heavy-
chain enhancer, Ets-1 cooperates with PU.1 (58). Ets-1 also
synergizes with the Jun-Fos heterodimer on the polyomavirus
enhancer (84). Myb and Ets-2 cooperation on the mim-1 pro-
moter has been reported (16). Cooperative DNA binding that
would relieve the inhibition observed in the full-length Ets-1
protein has not been reported. Thus, the molecular basis of the
transcriptional synergism is not known.
In a preliminary study, the polyomavirus enhancer-binding
protein 2/core-binding factor (CBF) (37, 81) has been shown to
enhance the binding of Ets-1 to the enhancer of the T-cell
receptor (TCR) b subunit gene (88). This putative interaction
is particularly interesting, since there is a juxtaposition of cbf
and ets binding sites in a number of TCR gene enhancers,
including the T-cell receptor alpha (TCRa) and TCRb chain
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enhancers (26, 34, 63). Interestingly, this arrangement also
forms a highly conserved unit in the enhancers of type C
mammalian leukemia viruses (22).
Extensive biochemical and genetic studies of cbf and ets
protein-binding sites have been performed on the enhancer of
Moloney murine leukemia virus (Mo-MLV). Biochemical data
obtained with proteins expressed in bacteria or purified from
thymus have established that CBF binds the Mo-MLV core site
present in each enhancer repeat (70, 81). CBF proteins are het-
erodimeric, with a DNA-binding subunit (CBFa) and a non-
DNA-binding subunit (CBFb) (37, 60, 61, 82). Three distinct
genes encode a family of CBFa subunits:Cbfa1 (AML3/Pebpa2a),
Cbfa2 (AML1/Pebpa2b), andCbfa3 (AML2/Pebpa2c) (1–3, 45, 56,
61, 86), while CBFb is encoded by an unrelated gene, Cbfb
(Pebpb2) (1, 48, 60, 82). Any of the CBFa subunits encoded by the
three Cbfa genes can associate with the CBFb subunit (1, 2, 36,
61). The CBFa proteins share a conserved 128-amino-acid do-
main, called the Runt domain (36) because of its conservation in
the Drosophila Runt protein (38). This domain mediates DNA
binding as well as dimerization to the CBFb subunit (36, 54).
Cbfa1 and Cbfa2 are expressed in a restricted number of cell
types, including thymus (55, 67), whereas Cbfa3 and Cbfb are
expressed ubiquitously (45, 60, 82). It is anticipated that any of the
CBFa proteins could bind the Mo-MLV enhancer, and this has
been confirmed for the protein encoded by the Cbfa2 gene (12).
Two binding sites for ets proteins, known as the LVb and
LVc sites, flank each of the cbf binding sites on the Mo-MLV
enhancer (Fig. 1). There are more than a dozen different ets
family proteins in vertebrates (39, 50, 83). The DNA-binding
domain is sufficiently conserved that the majority of ets pro-
teins bind similar sites: a conserved GGA sequence centered in
FIG. 1. Maps of expression and reporter plasmid constructs. (A) Mo-MLV reporter plasmids used in cotransfection assays. The sequence at the bottom is from the
promoter-proximal copy of the enhancer direct repeat. Binding sites for nuclear factors are shown in boxes (70). Point mutations in various binding sites are indicated
in lowercase letters above the sequence. Mutations are in both copies of the direct repeat (72). (B) TCRb enhancer reporter plasmids. pTCRbCAT contains the
Tb3-Tb4 sequence from the mouse TCRb enhancer positioned upstream of the herpesvirus thymidine kinase (tk) promoter and CAT gene. The ets and core recognition
sequences within Tb3 and Tb4 are shown below the sequence. pTCRb(Ets)CAT contains mutations in both ets sites; pTCRb(core)CAT contains mutations in all three
core sites. (C) Cbfa2 expression construct. A cDNA clone encoding a 451-amino-acid isoform of Cbfa2 (Cbfa2-451) was subcloned downstream from the CMV
promoter in the vector pcDNA/Amp to yield pcDNA/Cbfa2-451. (D) Expression constructs for ets proteins. The cDNA encoding each ets protein (Ets-1, Ets-2, Fli-1,
Elf-1, PU.1, GABPa, and GABPb) was subcloned downstream of the D. melanogaster actin 5c promoter to yield pPac/ets plasmids.
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a 9-bp region with less well conserved flanking sequences (9,
17, 52, 59, 78, 87, 91). In T lymphocytes, in which the core site
of Mo-MLV is functional, at least five different ets proteins are
expressed (Ets-1, Ets-2, Fli-1, GABP, and Elf-1 [4, 5, 44, 48,
75]). In vitro binding data have shown that both of the GGA
motifs of the Mo-MLV enhancer can be recognized by Ets-1
(27, 59). More extensive analysis of the LVb site demonstrates
that Ets-2, Fli-1, GABP, and an ets protein likely to be Elf-1
recognize this site (27).
In addition to the biochemical data indicating that sites in
the enhancer bind cbf and ets proteins, several lines of genetic
evidence suggest that these sites are key components of the
Mo-MLV enhancer. First, as mentioned above, the LVb site
and the core site are highly conserved in all mammalian C-type
retrovirus enhancers (22). Second, all three sites (LVb, core,
and LVc) are required for transcriptional induction by 12-O-
tetradecanoylphorbol-13-acetate in T cells. Mutations that dis-
rupt the binding of ets and cbf proteins also attenuate induction
(27, 72). Third, the Mo-MLV enhancer is preferentially active
in T cells (69), and mutations in the core site attenuate tran-
scription from both the Mo-MLV and the related SL3-MLV
enhancer preferentially in T cells (6, 72, 77). Mutations in the
LVb site attenuate the constitutive activity of the Mo-MLV
enhancer in multiple cell types, including T cells (27, 72).
Finally, evidence for the role of the core and LVb sites in
transcription of the Mo-MLV enhancer in T cells is the dra-
matic effect of mutations on the disease specificity of Mo-
MLV. Mo-MLV causes T-cell leukemias in mice; mutations in
either the LVb or core site result in a significant shift in disease
specificity from T-cell leukemia to erythroid leukemia (71).
In this report, we extend previous studies by using cDNAs
for cbf and ets proteins to study transactivation of the TCRb
and Mo-MLV enhancers. The data indicate that several ets and
cbf proteins cooperate in vivo. Binding sites for both families of
proteins are necessary for in vivo transactivation of the TCRb
and Mo-MLV enhancers by Ets-1, Ets-2, and GABP and by the
CBFa subunit encoded by the Cbfa2 gene. These findings
provide important functional data to support future biochem-
ical studies. Furthermore, these studies establish the partner-
ship of ets-cbf families as a model system with which to inves-
tigate synergism between eukaryotic transcription factors.
MATERIALS AND METHODS
Cell culture. Mouse embryonic carcinoma cell line P19 (kindly provided by
Jack Lenz) was cultured at 378C in 5% CO2 in Dulbecco’s modified Eagle’s
medium (Bethesda Research Laboratories [BRL]) supplemented with 10% heat-
inactivated fetal calf serum (Sigma), 100 U of penicillin per ml, 100 mg of
streptomycin (BRL) per ml, 2 mM L-glutamine (BRL), and 25 mM HEPES
(N-2-hydroxyethylpiperazine-N9-2-ethanesulfonic acid, pH 7.4). The Drosophila
melanogaster cell line S3 (kindly provided by Edward Berger) was maintained in
13 Drosophila Schneider medium (BRL) supplemented with 10% heat-inacti-
vated fetal calf serum at 258C.
Plasmids. The Mo-MLV reporter plasmids containing wild-type and mutated
Mo-MLV enhancers (a 384-bp fragment from the Mo-MLV U3/R region) linked
to the bacterial chloramphenicol acetyltransferase (CAT) gene were described
previously (72). Reporter plasmids containing the Tb3 and Tb4 elements from
the murine TCRb enhancer (25) were constructed by PCR. Three sets of primers
with BamHI overhangs were used to amplify the wild-type Tb3-Tb4 sequence
covering nucleotides 617 to 735 of the mouse TCRb enhancer (43) and to
introduce mutations into either ets or cbf binding sites [pTCRbCAT,
pTCRb(Ets)CAT, and pTCRb(core)CAT] (Fig. 1B). The sequences of the prim-
ers are as follows (lowercase letters indicate the mutated nucleotides):
TCRb(wt): sense, 59-CGGGATCCACAACAGGATGTGGTTTG-39, and anti-
sense, 59-CGGGATCCTTGAAGACAGGATGTGGC-39 (the Ets core is under-
lined); TCRb(Ets): sense, 59-CGGGATCCACAACAttATGTGGTTTGAC-39,
and antisense, 59-CGGGATCCTTGAAGACAttATGTGGCAAGTGTGG-39;
and TCRb(core): sense, 59-CGGGATCCACAACAGGATGTttTTTGACAT-39,
and antisense, 59-CGGGATCCTTGAAGACAGGATGTttCACGTGTttTTCC
CAAAATGC-39.
The PCR products were digested with BamHI and subcloned into the BamHI
site of pBLCAT2 (49). All fragments were subcloned in the same orientation
(617 to 735) relative to the herpesvirus thymidine kinase promoter, and the
nucleotide sequence was confirmed.
The eukaryotic expression vector pcDNA/Amp (Invitrogen) was used to ex-
press the CBFa subunit encoded by a cDNA derived from the murine Cbfa2
gene, which was isolated from a mouse thymus cDNA library (12). This cDNA
encodes a 451-amino-acid polypeptide (Cbfa2-451) identical to PEBP2aB1 (1,
3). An EcoRI fragment containing the complete open reading frame was sub-
cloned into pcDNA/Amp to give pcDNA/Cbfa2-451. Expression of Cbfa2-451 in
the pcDNA vector is from the cytomegalovirus (CMV) promoter.
The ets proteins were expressed from the D. melanogaster actin 5c promoter-
based pPac expression vector (42). Murine cDNA clones bearing the open
reading frames of Ets-1, Fli-1, Elf-1, GABPa, and GABPb (amino acids 2 to 440,
1 to 452, 1 to 619, 1 to 454, and 1 to 380, respectively) were engineered with six
consecutive histidine codons (and a BamHI linker) at the N-terminal end of the
open reading frame. Murine cDNAs of Ets-2 (encoding amino acids 1 to 468)
and PU.1 (1 to 271) spanning the entire open reading frames were ligated into
the pPac vector in their native forms.
Transfections and CAT assays. P19 cells were seeded at 7 3 106 cells per
60-mm dish 1 day before transfection. Transient transfections were performed
with LipofectAmine reagent (BRL) following the manufacturer’s instructions.
Typically, 2 mg of the reporter plasmids and 0.1 to 8.0 mg of the pcDNA/Cbfa2-
415 expression vector were mixed with 9 ml of LipofectAmine reagent for each
transfection. The total amount of expression vector DNA in each transfection
was held constant at 10 mg by the addition of either the empty expression vector
pBKCMV (Stratagene) or pcDNA/Amp, to ensure that the amount of CMV
promoter was equivalent in each transfection. After 5 h of incubation in serum-
free medium containing the DNA-LipofectAmine mixture, serum was added to
each dish to 10% final concentration. The cells were harvested 48 h after trans-
fection. Cell lysates were prepared by freeze-thawing by standard protocols (40).
Drosophila S3 cells were plated at 3 3 106 per 25-cm2 flask and cotransfected
24 h later with 5 mg of reporter plasmid and 0.5 to 8.0 mg of expression plasmid
by calcium phosphate precipitation. The total amount of DNA was held constant
(15 mg) by the addition of nonrecombinant pPac expression vector. Thus, the
concentration of Drosophila actin promoter was the same in each transfection.
The DNA was mixed with 375 ml of 0.25 M CaCl2 and then added dropwise to
375 ml of 23 HBS (3 mM Na2HPO4, 5 mM KCl, 140 mM NaCl, 25 mM HEPES
[pH 7.1]). After 30 min of incubation at room temperature, the slightly cloudy
mixture was added to the cells. The flasks were left undisturbed until the time of
harvest 48 h later. Cell lysates were prepared by four rounds of freeze-thawing.
CAT activities were determined as described by Gorman et al. (24). Assay
results were normalized to the total protein content of each lysate, and the
mixtures were incubated with 0.1 mCi of [14C]chloramphenicol (New England
Nuclear). The conversion of [14C]chloramphenicol substrate to its mono- and
diacetylated forms was monitored by thin-layer chromatography and quantified
by PhosphorImager scanning.
DNA-binding assays. Complementary 21-bp oligonucleotides containing the
wild-type Tb3 sequence [Tb3(WT): ACAACAGGATGTGGTGGTACA], mu-
tations in the ets binding site [Tb3(Ets): ACAACAttATGTGGTGGTACA], and
mutations in the core site [Tb3(core): ACAACAGGATGTttTGGTACA] were
synthesized, annealed, and end labeled with [g-32P]ATP. Electrophoretic mobil-
ity shift assays were performed as described previously (81).
Protein expression and purification. A DNA fragment encoding a 17-kDa
DNA-binding (Runt) domain from the mouse Cbfa2-415 protein (amino acids
51 to 202) was amplified by PCR with the following primers: 59 (sense) primer,
CGGAATTCCCATATGGTGGAGGTACTAGCT; 39 (antisense) primer, CG
GATCCTTACTCCAATTCACTGAGCCG. The amplified fragment was di-
gested with NdeI and BamHI and subcloned into the NdeI and BamHI sites of a
modified pET3 vector lacking the codons of T7 gene 10 (59). The plasmid was
transformed into Escherichia coli BL21(DE3) containing the pLysS plasmid (73).
Expression was induced with 0.4 mM IPTG (isopropylthiogalactopyranoside) for
3 h at 378C to an optical density at 600 nm of 0.3 to 0.4 at the time of induction
and 1 to 1.5 at the time of harvest. The bacterial cell pellet was disrupted by three
freeze-thaw cycles in lysis buffer (50 mM Tris [pH 8.1] plus protease inhibitors:
1 mM pefablock, 1 mg of leupeptin per ml, 2 mg of aprotinin per ml, and 1 mg of
pepstatin per ml; the volume was 1/10 the volume of original bacterial culture)
and sheared with a 22-gauge needle, and the soluble protein fraction was col-
lected following centrifugation (16,000 3 g, 15 min, 48C) (11).
The amino-terminal deletion mutant polypeptide of murine Ets-1 (DN331)
was produced in bacteria, and pure protein was prepared as described previously
(15).
RESULTS
CBF stimulates transcription from the Mo-MLV and TCRb
enhancers. CBF was first tested for its ability to transactivate
the Mo-MLV and TCRb enhancers in a transient-cotransfec-
tion assay in the P19 mouse embryonic carcinoma cell line. A
cDNA encoding only an a subunit of CBF was used. Neither
the Cbfa1 (Pebpa2a) nor Cbfa2 (AML1/Pebpa2b) gene is ex-
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pressed in P19 cells (1, 61). The b subunit of CBF is expressed
ubiquitously, and presumably this polypeptide was provided by
the P19 cells. Consistent with this hypothesis, coexpression of
both CBF subunits transactivated the Mo-MLV and TCRb
enhancers to the same extent as expression of the CBFa sub-
unit alone (data not shown). The CBFa subunit that was used
for these analyses is one of three isoforms encoded by the
Cbfa2 gene (1, 3, 12). This isoform, termed Cbfa2-451, con-
tains 451 amino acids, has a predicted molecular mass of 48.6
kDa, and is identical to PEBP2aB1 (1, 3).
Cbfa2-451 stimulated transcription from both the pMoCAT
and pTCRbCAT reporter constructs (Fig. 2; see also Table 1
for data summary). The maximum stimulation by Cbfa2-451
was approximately six- to eightfold on both reporter con-
structs. Transactivation peaked at 2 to 4 mg of input Cbfa2-451
expression vector and declined at higher doses, suggesting that
excess CBFa2-451 protein squelched some necessary compo-
nent of the transcription apparatus (1, 64).
Several ets proteins, Ets-1, Ets-2, GABPa/b, Fli-1, PU.1,
and Elf-1, were also tested for their ability to transactivate
pMoCAT and pTCRbCAT. None of the ets proteins stimu-
lated transcription from either reporter construct in P19 cells,
either alone or in conjunction with Cbfa2-451 (data not
shown). Our interpretation of this negative result is that one or
more endogenous ets proteins in P19 cells may be present in
saturating amounts.
Both ets and core motifs are required for transcriptional
activation of the Mo-MLV and TCRb enhancers by CBF. To
identify the cis-acting sequences in the Mo-MLV enhancer
required for transactivation by CBF, wild-type and mutated
reporter constructs that contained base substitutions in indi-
vidual protein-binding sites were used in transactivation assays
(Fig. 1). Disruption of the binding site for CBF [pMo(core)
CAT] resulted in loss of transactivation by Cbfa2-451, as ex-
pected (Fig. 3). Mutation of one of the adjacent binding sites
for the ets proteins, the LVb site [pMo(LVb)CAT], also dis-
rupted transactivation by Cbfa2-451. In contrast, mutation of
other protein-binding sites, such as the GRE (binding site for
the glucocorticoid hormone receptor and the bHLH protein
SEF2 [10, 14]), the nuclear factor 1 (NF1) binding site (66),
and another ets binding site, LVc, did not affect transactivation
by Cbfa2-451. Thus, it appears that transactivation of the Mo-
MLV enhancer by Cbfa2-451 requires some protein endoge-
nous to P19 cells that associates with the LVb site. Transacti-
vation by Cbfa2-451 does not, however, require the other ets
binding site in the Mo-MLV enhancer, the LVc site. This is
consistent with previous results demonstrating that the LVc
site has no role in constitutive expression from the Mo-MLV
enhancer in T cells (27, 72).
Transactivation of the TCRb enhancer by Cbfa2-451 also
required intact cbf and ets binding sites; mutations in either of
these sites resulted in decreased levels of transactivation (Fig.
4). The similar results of the mutational analysis in both the
Mo-MLV and TCRb enhancers highlight the cbf-ets cassette as
a distinct functional unit within these multicomponent enhanc-
ers.
Both ets and cbf binding sites are required for ets proteins to
transactivate the TCRb enhancer in Drosophila S3 cells. Be-
cause the ets proteins did not transactivate either the Mo-MLV
or TCRb enhancer in mouse P19 cells, we chose a second cell
line for further analysis, Drosophila S3 cells. Enhancers bearing
both wild-type and mutant versions of the ets binding sites were
tested in transactivation assays (Fig. 5). Only transactivation
that depended upon intact ets sites was interpreted. Ets-1 stim-
ulated transcription from the TCRb enhancer at least 15-fold
in S3 cells, Ets-2 gave a 5-fold activation, and GABPa/b trans-
activated the TCRb enhancer approximately 3-fold. Note that
the total level of transactivation of the TCRb enhancer by
GABPa/b was 16-fold, but that much of this transactivation
was independent of the mutated GGA sequences [Fig. 5C,
compare pTCRbCAT and pTCRb(Ets)CAT]. Elf-1-depen-
dent transactivation was not at all dependent on the ets sites,
and Fli-1 did not transactivate pTCRbCAT (data not shown).
The activity of the ets proteins on the Mo-MLV enhancer
was tested in S3 cells. The extent of transactivation was much
less than that observed with the TCRb enhancer and was not
reproducible (data not shown). We suspect that higher basal
transcription from the Mo-MLV enhancer than from the
FIG. 2. Cbfa2-451 transactivates the Mo-MLV and TCRb enhancers in a
dose-responsive manner. The CBF expression vector pcDNA/Cbfa2-451 was
cotransfected with 2 mg of either the pMoCAT (F) or pTCRbCAT (E) reporter
plasmid into P19 cells. Transcription activity of reporter plasmids was deter-
mined by CAT assays as described in Materials and Methods. The fold activation
was calculated as the CAT activity induced by transfection of the pcDNA/Cbfa2-
451 expression vector relative to the CAT activity induced by transfection with an
empty expression vector. Three independent experiments were conducted. The
results from one experiment performed with duplicate transfections are plotted
(means 6 standard deviation). The maximal transactivation varied from 5- to
7-fold on the pMoCAT reporter and 6- to 10-fold on the pTCRbCAT reporter
in independent experiments, and the amount of pcDNA/Cbfa2-451 expression
vector that induced maximal transactivation varied between 2 and 4 mg.
TABLE 1. Summary of positive transactivation results
Transactivator Cell line
Reporter activitya
Mo-MLV TCRb
WT Core ets WT Core ets
pcDNA/Cbfa2-451 P19 1b 2 2 1 2 2
pPac/Ets-1 S3 1 2 2
pPac/Ets-2 S3 1 2 2
pPac/GABPa/b S3 1 2 2
a CAT activity: 1, transactivator induced a level higher than in controls with
empty expression vector; 2, no change relative to controls. The core and ets
reporters were mutated in the core or ets binding site, as indicated. WT, wild
type.
b Transactivation of Mo-MLV enhancers containing mutations in LVc, NF1,
or GRE sites was equivalent to that of the wild-type enhancer.
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TCRb enhancer made it more difficult to transactivate by ad-
dition of exogenous ets proteins.
The role of the cbf binding sites in the transactivation by
several ets proteins in Drosophila S3 cells was also tested.
Mutation of the cbf binding sites in the TCRb enhancer
[pTCRb(core)CAT] reduced ets-dependent transactivation to
the same level as mutation of the ets binding sites (Fig. 5).
These findings suggest that transactivation by Ets-1, Ets-2, and
GABPa/b requires interaction with endogenous Drosophila
homologs of the CBFa and b subunits, called Runt and
Brother, respectively (13, 19, 38, 61).
Cbfa2-451 did not transactivate expression from either the
Mo-MLV or TCRb enhancer in S3 cells. As in the case of the
P19 cells and endogenous ets proteins, we propose that S3 cells
contain saturating levels of an endogenous CBF homolog. This
proposal is consistent with the observations that the Drosophila
Runt/Brother heterodimer binds the same consensus core site
as the mammalian CBF complex (19, 36).
Several additional cell lines (Rat-2, NIH 3T3, HeLa, and
SL2) were tested for their ability to support transactivation of
the Mo-MLV and TCRb enhancers by Cbfa2-451 and the ets
proteins. No cell line was found in which both Cbfa2-451 and
the ets expression vectors, independently or together, would
direct transactivation of these enhancers. Therefore, we were
unable to perform reconstitution experiments to examine syn-
ergistic activation by Cbfa2-451 and specific ets proteins.
DNA-binding domains of Ets-1 and Cbfa2 bind simulta-
neously to the TCRb enhancer. The ets and cbf binding sites in
the Mo-MLV and TCRb enhancers are very closely aligned.
They are particularly close in the TCRb enhancer, with only a
5-bp center-to-center distance between the two sites. One pos-
sible explanation for the observation that mutating the ets site
disrupts transactivation by Cbfa2-451 is that the mutation also
disrupts CBF binding. Reciprocally, the inability of Ets-1,
Ets-2, or GABPa/b to transactivate the TCRb enhancer with
mutated cbf binding sites could be caused by their inability to
bind. To exclude these trivial explanations, simultaneous bind-
ing of Ets-1 and Cbfa2 to wild-type and mutated TCRb en-
hancers was demonstrated.
FIG. 3. Transactivation of the Mo-MLV enhancer by Cbfa2-451 requires
both intact core and LVb sites. The pcDNA/Cbfa2-451 expression plasmid was
cotransfected with 2 mg of the indicated Mo-MLV reporter plasmids in P19 cells,
and transactivation relative to the reporter plasmids alone was plotted as de-
scribed in the legend to Fig. 2. The letters in parentheses indicate the binding site
that is mutated [e.g., pMo(LVb)CAT contains a 2-bp mutation in each LVb site
in both copies of the enhancer direct repeat; pMo(NF1)CAT contains mutations
in both the NF1(a) and NF1(b) sites (see Fig. 1)]. A dose-response curve was
generated for each reporter construct; the data shown are from experiments
performed with 4 mg of pcDNA/Cbfa2-451. Four independent experiments were
performed; data illustrate one representative experiment.
FIG. 4. Transactivation of the TCRb enhancer by Cbfa2-451 also requires
intact binding sites for ets and cbf proteins. P19 cells were cotransfected with 4 mg
of pcDNA/Cbfa2-451 and 2 mg of wild-type (pTCRbCAT) or mutated
[pTCRb(Ets)CAT and pTCRb(core)CAT] reporter constructs. Four indepen-
dent experiments were performed; transfections from one representative exper-
iment are shown graphically on top and numerically in the table below. Analyses
were performed as described in the legend to Fig. 2.
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Truncated versions of Ets-1 and Cbfa2 which retain the
DNA-binding domains and minimal flanking sequences (Ets-
1DN331 and CBFa2RD, respectively) were tested for binding
to the Tb3 site (25) in the TCRb enhancer by the mobility shift
assay. Both Ets-1DN331 and CBFa2RD form distinct DNA-
protein complexes on the wild-type Tb3 probe (Fig. 6, lanes 1
and 2). Adding both Ets-1DN331 and CBFa2RD generates a
third shifted complex (Fig. 6, lane 3). This complex migrates
more slowly than either the Ets-1DN331 or CBFa2RD protein-
DNA complex, suggesting that it represents the simultaneous
binding of both proteins.
The mutations introduced into the ets site abolished the
association of Ets-1DN331 (Fig. 6, lane 4). Importantly, despite
its proximity to the cbf binding site, the ets site mutation did
not disrupt binding by CBFa2RD (Fig. 6, lane 5). Similarly,
mutations in the cbf binding site abolished CBFa2RD but not
Ets-1DN331 binding (Fig. 6, lanes 6 and 7). Therefore, the
inability of Cbfa2-451 to stimulate transcription from enhanc-
ers lacking intact ets sites and of the ets proteins to transacti-
vate an enhancer with core site mutations was not due simply
to their inability to bind to the enhancers.
DISCUSSION
Transactivation experiments in P19 cells demonstrate that a
CBFa subunit encoded by the mouse Cbfa2 gene (Cbfa2-451)
stimulates transcription from both the Mo-MLV and TCRb
chain enhancers in vivo. Transactivation by Cbfa2-451 is de-
pendent on a nearby GGA sequence in both enhancers. Mu-
tation of both guanines in the GGA sequence does not disrupt
Cbfa2-451 binding in vitro. These data strongly suggest that
transactivation by Cbfa2-451 requires an endogenous protein
in P19 cells whose binding is dependent on one or both of these
guanines.
FIG. 5. Both ets and cbf sites are necessary for ets proteins to transactivate the TCRb enhancer. Five micrograms of the indicated TCRb enhancer reporter plasmids
was cotransfected with 2 mg of (A) Ets-1, (B) Ets-2, or (C) GABPa plus GABPb expression constructs. Four independent transfections were performed in the D.
melanogaster cell line S3, and the fold activation relative to the reporter construct plus empty pPac expression vector for one representative experiment is shown. Data
were collected and presented as described in the legend to Fig. 2.
FIG. 6. Binding of Ets-1 and Cbfa2 to wild-type and mutated Tb3 sites in the
TCRb enhancer. The DNA-binding activity of Ets-1DN331 and CBFa2RD was
tested in the mobility shift assay on Tb3(WT), Tb3(Ets), and Tb3(core) probes,
as indicated. Reaction mixtures contained approximately 4 ng of purified Ets-
1DN331 or 200 ng of extract prepared from bacteria expressing CBFa2RD
protein and less than 10 fmol of radiolabeled probe. Lanes: 1, 4, and 6, Ets-
1DN331; 2, 5, and 7, CBFa2RD; 3, Ets-1DN331 and CBFa2RD. The positions of
protein-DNA complexes are indicated by arrowheads.
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Several types of data suggest that ets proteins are the most
likely candidates for the Cbfa2-451 accessory protein. First,
the ets proteins are the only known proteins that bind the GGA
sequence in both the TCRb and the Mo-MLV enhancers. A
non-ets protein, the mammalian C-type retrovirus enhancer
factor 1 (MCREF-1), also binds the LVb site in the Mo-MLV
enhancer (51, 74). However, a site for MCREF-1 (consensus:
CNGGN6CNGG) does not overlap the GGA motif in the
TCRb enhancer fragment. The distance between the GGA
motif and the core site is not conserved in the TCRb and
Mo-MLV enhancers, and this variability is also consistent with
binding by an ets protein. In fact, the center-to-center distance
from the GGA sequence to the core site is 5 bp further in the
Mo-MLV enhancer than in the TCRb enhancer, which would
position binding proteins on different sides of the B-form DNA
helix in the two enhancers. This is consistent with in vitro
binding data that show the insensitivity of ets proteins to sub-
stantial changes in the orientation and spacing between their
binding sites and those of their accessory proteins. For exam-
ple, the spacing between the binding sites for Elk-1 and the
SRF has no affect on the ability of these two proteins to form
a ternary complex (78). Cooperative binding between Ets-1
and CBF also has been shown to be indifferent to spacing
between the ets and cbf sites (88). Possible candidates for ets
family members in P19 cells include PEA3 and Ets-2, both of
which are expressed in undifferentiated embryonal carcinoma
cells (53, 90).
In another set of studies, transactivation of the TCRb en-
hancer by the ets proteins Ets-1, Ets-2, and GABPa/b was
demonstrated. Importantly, the activity of these ets proteins in
Drosophila S3 cells is dependent on the integrity of the adja-
cent cbf binding site. We speculate that the ets proteins are
cooperating with an endogenous Drosophila cbf homolog to
activate transcription. The obvious candidate for this core-
binding factor is Runt, theDrosophila protein that is the found-
ing member of the CBFa protein family (36, 38), or a partially
characterized runt homolog (19).
These functional studies indicate that cbf and ets proteins
cooperate to activate transcription from the Mo-MLV and
TCRb enhancers in vivo. Although it is certainly possible that
other, as yet unidentified, proteins may be cooperating with
CBF or the ets proteins on these two enhancers, the most
straightforward explanation is that one or more members of
the ets family are cooperating with one or more members of
the cbf family of proteins.
Three ets proteins, Ets-1, Ets-2, and GABP, activated tran-
scription from the TCRb enhancer in Drosophila S3 cells.
However, the ets protein Fli-1 did not transactivate the TCRb
enhancer in Drosophila cells. Elf-1 transactivated the TCRb
enhancer, but transactivation did not require intact ets binding
sites in the Tb3 and Tb4 elements. Thus, activation by Elf-1
was presumably mediated by Elf-1 binding sites elsewhere on
the pTCRbCAT construct. Although we have not tested for
variable expression of the ets proteins that could account for
these differences in transactivation activity, we were struck by
the following interesting correlation that could also explain
these differences: the ability of the ets proteins to transactivate
the TCRb enhancer roughly correlated with their predicted
binding affinity for the Tb3 and Tb4 sites. The ‘‘selected’’
consensus sequences for Ets-1, GABPa, Fli-1, and Elf-1 bind-
ing sites are shown in Table 2. The predicted order of binding
affinity for the TCRb ets sites is Ets-1 5 Ets-2 . GABPa .
Fli-1 .. Elf-1. The most critical nucleotide in this prediction
is that at position 7, which is a T residue in both the Tb3 and
Tb4 sites. Ets-1 (and presumably Ets-2, which displays 95%
amino acid identity in the ETS domain) binds equally well to
GGA sequences containing either a T or an A at position 7 (59,
87). GABPa binds to both GGAA and GGAT sequences but
prefers a GGAA site (9), and Fli-1 has an even greater pref-
erence for GGAA sequences but can bind to GGAT (52). Elf-1
is unusual among the mammalian ets proteins insofar as it
binds only GGAA sequences (7, 80). These predicted affinities
correlate with the relative abilities of ets proteins to transacti-
vate the TCRb enhancer; Ets-1, Ets-2, and GABP transacti-
vate with the ranking Ets-1 . Ets-2 . GABP, while Fli-1 and
Elf-1 show no transactivation. Ets-1, GABP, and Elf-1 have
been reported to be abundant GGA-binding activities in T-cell
extracts (27, 89). Taken together, these data predict that Ets-1
and GABP contribute significantly to transcription from the
Mo-MLV and TCRb enhancers in T cells and do so in collab-
oration with CBF.
From the data presented here and by analogy to the well-
characterized Elk-1 and SRF interaction, we propose the fol-
lowing mechanism for CBF cooperation with Ets-1, Ets-2, and
GABP. Each of these intact ets proteins has attenuated DNA-
binding activity which can be enhanced by deletion of amino-
terminal sequences (28, 47, 59, 76, 85). Quantitative analyses
have shown that the low affinity of Ets-1 DNA binding is due
to instability of the DNA-protein complexes (35). This has also
been reported for GABP (76). Thus, we propose that CBF
stabilizes DNA-bound Ets-1, Ets-2, and GABP. Second, we
predict that the cbf and ets proteins each contain a domain that
is responsible for the cooperative interaction. A candidate
domain for the ets proteins Ets-1, Ets-2, and GABPa is a
region of high conservation in the amino-terminal half of these
proteins, known as the pointed domain or putative HLH re-
gion (23, 41). There are two possible locations for an interac-
tive domain in CBF: either the DNA-binding domain of the
CBFa subunit, which is highly conserved between Runt and
the mammalian CBFa proteins, or sequences in the non-DNA-
binding CBFb subunit that are conserved between the mam-
malian CBFb and Drosophila Brother proteins (19). Cross-
species interactions have been reported for Elk-1, in that Elk-1
interacts with the conserved DNA-binding domain of both
mammalian SRF and its yeast homolog MCM1 (57). Finally,
since cooperative binding between Ets-1 and CBF is relatively
indifferent to the spacing between ets and core sites (88), we
predict that the putative CBF interaction domain in Ets-1 is
connected to the DNA-binding ETS domain by a flexible hinge
linker. Preliminary data for such a hinge region have recently
been obtained from structural studies of Ets-1 polypeptides
(62).
TABLE 2. Nucleotide sequence preferences of ets proteinsa
Protein
Nucleotide(s) at position:
1 2 3 4 5 6 7 8 9
Consensus N N N G G A N N N
Ets-1 A, g C C, a G G A A, T G, a C, T
GABPa G, A C, g C, a G G A A, t G, a T, c
Fli-1 A C C G G A A G, a T, c
E74/Elf-1 C, T C C, a G G A A* G, a T
Tb3/Tb4 A C A G G A T G T
a Optimal sequences for Ets-1 (59, 87), GABPa (9), and Fli-1 (52) were
determined by selected and amplified binding site analysis. The E74/Elf-1 se-
quence was determined for E74, a closely related Drosophila homolog of Elf-1
(79). Two uppercase letters at a position indicate approximately equal selection;
a lowercase letter indicates a less-favored nucleotide. The sequence in the TCRb
enhancer is listed at the bottom for comparison. The asterisk at position 7 for
E74/Elf-1 indicates that binding is restricted to sites with an A at this position
(80).
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One conundrum that will direct future studies is the appar-
ent promiscuity of Ets-1 and CBF for different partners. Ets-1
has now been reported to interact with five unrelated proteins:
Jun-Fos, Sp1, PU.1, TFE-3, and CBF (18, 34, 58, 84, 88; this
study). This promiscuity is difficult to reconcile with the hy-
pothesis that these interactions are mediated by a specific
domain on the Ets-1 protein. Does Ets-1 contain a separate
interaction domain for each of these proteins or one interac-
tion domain that binds to all of these proteins? The same
problem exists for CBF, which has now been reported to re-
quire two different accessory proteins to activate transcription:
an ets protein on the TCRb chain enhancer, and c-Myb on the
TCRd enhancer (29). As soon as adequate amounts of pure,
full-length Cbfa2 subunit are available for biochemical analy-
ses, the experiments necessary to resolve these questions and
determine the molecular basis of the cbf-ets partnership can be
performed.
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